SECsense Logo

Ascendis Pharma A/S January 2025 SEC Filing: Warrant Grants and Corporate Insights

$ASND
Form 6-K
Filed on: 2025-01-15
Source
Ascendis Pharma A/S January 2025 SEC Filing: Warrant Grants and Corporate Insights

Here are the key insights extracted from the financial report (Form 6-K) for Ascendis Pharma A/S:

  1. Report Type and Date:
  • This is a Form 6-K filing submitted to the SEC.
  • The report is for the month of January 2025.
  1. Company Information:
  • Name: Ascendis Pharma A/S
  • Address: Tuborg Boulevard 12, DK-2900 Hellerup, Denmark.
  • Commission File Number: 001-36815.
  1. Warrant Grants:
  • On January 14, 2025, the board of directors granted a total of 82,103 warrants to certain employees under Appendix 1a of the Company’s Articles of Association.
  • Each warrant allows the holder to subscribe for one ordinary share of Ascendis Pharma A/S at an exercise price of $131.57 per share, which is equivalent to the closing price of the American Depositary Shares (ADS) on the grant date.
  • Vesting Schedule:
    • 25% of the warrants will vest on the one-year anniversary of the grant date.
    • The remaining 75% will vest at a rate of 1/36th per month following the first anniversary, contingent on continued employment.
    • There are provisions for earlier vesting upon the occurrence of certain exit events.
  1. Future Grants:
  • After the current warrant issuance, the company has 1,978,013 additional warrants available for future grants according to its Articles of Association.
  1. Incorporation by Reference:
  • The report is incorporated by reference into the registration statements on Form S-8 and Form F-3 for Ascendis Pharma A/S, indicating that this information is part of the official filings with the SEC.
  1. Signatory:
  • The report was signed by Michael Wolff Jensen, Executive Vice President and Chief Legal Officer, on January 15, 2025.

This summary highlights significant corporate actions regarding employee compensation, specifically through warrant grants, as well as essential company and filing information relevant to investors and stakeholders.